Global Bovine Mastitis Market is estimated to be valued at USD 1,562.9 Mn in 2024, exhibiting a CAGR of 5.2% over the forecast period 2024-2031. The market is projected to grow at a substantial rate owing to factors such as rising consumption of dairy products and increasing adoption of mastitis detection tools by dairy farmers. Furthermore, growing awareness regarding animal health and economic losses incurred due to mastitis is also contributing to market growth.
Market Dynamics:
The bovine mastitis market is driven by increasing dairy consumption globally as well as rising adoption of mastitis detection tools by dairy farmers. Dairy consumption has been increasing steadily owing to growth in global population and rising health awareness. As dairy products contain important nutrients, there has been a surge in demand. This has compelled dairy farmers to optimize milk production and quality, propelling adoption of mastitis detection and treatment products. Additionally, mastitis leads to economic losses in terms of reduced milk production and increased treatment costs. Thus, dairy farmers are increasingly using sensors, detectors and other tools to identify cows suffering from mastitis at an early stage in order to initiate timely treatment and minimize losses. This factor is also fueling revenue growth of the bovine mastitis market.
Increase in milk production driving demand for bovine mastitis treatment
One of the major drivers of the bovine mastitis market is the increasing demand for milk and milk products globally. Mastitis significantly impacts milk production from dairy cows by reducing milk yield. Left untreated, mastitis can lower milk production by as much as 225 pounds per cow per lactation. Therefore, farmers and dairy producers are increasingly adopting effective treatment and prevention practices to control mastitis in dairy cows. This is driving the demand for antibiotic formulations, teat dips, topical therapies, and other treatments that help increase milk yields.
Rising dairy cattle population augmenting market growth
Another driver boosting the bovine mastitis market is the steadily growing population of dairy cattle worldwide. Countries with large dairy industries like the United States, China, India, Brazil, and Australia are witnessing an uptrend in dairy cattle numbers to meet the rising demand for milk. Since dairy cows are more prone to contracting mastitis, an expanding dairy cattle pool is directly proportional to an increasing patient base requiring bovine mastitis treatment. Vaccines, antibiotics, and other products are being widely used to both prevent and cure mastitis among the growing dairy herds. This steady growth in the cattle population acts as a key demand stimulant for the market.
Stringent regulations on antibiotic residues constraining market potential
One important restraint on the bovine mastitis market is the strict regulations imposed on antibiotic residues in milk. Most countries have set Maximum Residue Limits (MRLs) for different antibiotic compounds in milk. Exceeding these MRLs can render the milk unfit for human consumption and impose heavy fines on dairy farms. The implementation of stringent quality norms is forcing farmers and drug makers to shift from traditional antibiotic-based mastitis treatments to alternative therapies. This regulatory constraint creates roadblocks in the full realization of market potential for antibiotic-based formulations.
Rising preference for organic dairy products limiting antibiotic use
The increasing consumer demand for organic and residue-free dairy products is another significant restraint challenging the bovine mastitis market. Organic dairy farmers are barred from using conventional antibiotic therapies to treat mastitis as per regulatory standards. They rely more on nutritional and alternative remedies, which are costlier and less effective than pharmaceuticals. The thriving market for organic milk is steering dairy producers away from mass antibiotic usage, which negatively impacts the sales of common mastitis drug formulations.
Emergence of rapid on-farm mastitis detection tools opening new avenues
One of the major opportunities for market participants is the development of advanced on-farm mastitis detection solutions. Traditional kalazar detection methods can only identify clinical mastitis but fail to diagnose subclinical mastitis in the early stages. Novel technologies like automated milk analyzers, electrical conductivity devices, and inflammation sensor tags allow rapid screening of individual cows as well as bulk milk. Their adoption helps initiate early mastitis treatment, reducing the risk of economic losses due to lowered milk yields. The emergence of rapid diagnostic equipment presents lucrative business prospects.
Growing popularity of natural remedies expanding alternative product segment
Another key opportunity for bovine mastitis market competitors lies in the alternative therapies segment. With the rising disinclination towards antibiotic residues, natural remedies sourced from herbs and plants are gaining increasing acceptability. Products containing aloe vera, turmeric, garlic, echinacea, and other botanicals to prevent and cure mastitis are witnessing higher demand. Market players are actively engaging in the R&D of safe, cost-effective, and efficacious natural treatment options. This growing emphasis on all-natural remedies is opening up new avenues for bio-based mastitis treatment portfolios.
Link - https://www.coherentmarketinsights.com/market-insight/bovine-mastitis-market-4947
Key Development
- In September 2022, Boehringer Ingelheim, a global leader in animal health, announced that the Clinical and Laboratory Standards Institute (CLSI) had accepted improved interpretation criteria for Ubrolexin susceptibility testing. The Federation of Veterinarians of Europe recommends conducting susceptibility testing wherever possible to determine which antimicrobial will be most effective in treating a certain illness. The ability to analyze the susceptibility of a mastitis-specific antibiotic combination enables veterinarians to choose the best treatment option while preventing resistance.
Key Players: Zoetis, Merck & Co., Inc., Boehringer Ingelheim International GmbH, Bayer AG, Elanco, Ceva, West Way Health, Norbrook, DeLaval, ImmuCell Corporation, Advanced Animal Diagnostics, and Nimrod Veterinary Products Ltd.
